Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ribociclib
Find trials that include:  Any drugs shown
Results 1-24 of 24 for your search:
Start Over
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011A2404, NCI-2016-01811, NCT02941926
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011H2301, NCI-2017-00678, NCT03081234
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011G2301, NCI-2017-00973, 2014-001795-53, NCT03078751
Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011X2110C, NCI-2015-01657, NCT02292550
Ribociclib, Docetaxel. and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 145515, NCI-2015-01797, 15-15745, CLEE011XUS07T, NCI-2015-01701, NCT02494921
Ribociclib with Trastuzumab or Trastuzumab Emtansine in Treating Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Tissue collection/Repository
Age: 18 and over
Trial IDs: 15-530, NCI-2016-00505, NCT02657343
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011XUS29, NCI-2016-00995, NCT02732119
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CTMT212X2106, NCI-2016-01156, 2015-005019-34, NCT02703571
Enzalutamide with or without Ribociclib in Treating Patients with Metastatic Hormone-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15G.322, NCI-2015-01454, 2015-055, c15-153, CLEE011XUS12T, OHR-8, NCT02555189
A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: CLEE011XUS17T, NCI-2016-01570, NCT02607124
Ribociclib and Chemoembolization in Treating Patients with Advanced Liver Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: STU 052015-073, NCI-2016-01830, NCT02524119
Ribociclib and Bicalutamide in AR+ TNBC
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BTCRC BRE15-024, NCI-2017-00974, NCT03090165
Ribociclib and Letrozole in Treating Patients with Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1561, NCI-2015-02181, NCT02657928
Letrozole with or without Ribociclib before Surgery in Treating Women with Stage II-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011XUS10T, NCI-2016-00423, STUDY00002972, NCT02712723
Fulvestrant with or without Ribociclib in Patients with Recurrent, Unresectable, or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AAAP9506, NCI-2016-01092, NCT02632045
Ribociclib and Everolimus in Treating Patients with Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-1535, NCI-2017-00449, NCT03070301
Ribociclib (LEE011) Rollover Study for Continued Access
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: CLEE011X2X01B, NCI-2017-00789, NCT02934568
Ribociclib and Everolimus in Treating Patients with Locally Advanced, Metastatic, or Refractory Dedifferentiated Liposarcoma or Leiomyosarcoma
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SAR-096, NCI-2017-00930, NCT03114527
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2106, NCI-2013-01630, NCT01857193
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2107, NCI-2014-00139, 2013-001219-57, NCT01872260
Ribociclib and Paclitaxel in Treating Patients with Metastatic Rb+ Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 06115, NCI-2016-00169, NCT02599363
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLSZ102X2101, NCI-2016-00957, 2015-004016-38, NCT02734615
A Phase 1B Study of Ribociclib in Combination with Doxorubicin in Advanced Soft Tissue Sarcomas
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 and over
Trial IDs: STUDY00016070, NCI-2016-01794, NCT03009201
Ribociclib with Carboplatin and Paclitaxel in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2016.131, NCI-2017-01120, NCT03056833
Start Over